4Month9On the 11th, the executive committee meeting of the pharmacopoeia Committee was held in Beijing. The meeting heard the report of the National Pharmacopoeia Commission on2020The report on the preparation of the annual edition of the Chinese Pharmacopoeia was considered and adopted.2020Draft Chinese Pharmacopoeia. Lan Fen, Secretary-General of the State Pharmacopoeia Commission, reported to all the Executive Committee2020The preparation of the annual edition of the Pharmacopoeia.

2020 Edition of Chinese Pharmacopoeia New Varieties319species, revised3177species, no longer collected10species, variety adjustment combined4Species, a total of collected varieties5911species, three of which are biological products153species, of which new20species, revision126Species; New General Rules for Biological Products2Overall4A.

At the meeting, Zhang Boli, academician of the Chinese Academy of Engineering, Chen Kaixian, academician of the Chinese Academy of Sciences, and Wang Junzhi, academician of the Chinese Academy of Engineering, respectively made keynote speeches on the overall situation, outstanding characteristics and suggestions for the next step of the pharmacopoeia on behalf of the fields of traditional Chinese medicine, chemical medicine, and biological products.

Institutional members from relevant departments such as the Ministry of Industry and Information Technology, the National Civil Affairs Commission, the National Health Commission, the National Medical Insurance Administration, the State Administration of Traditional Chinese Medicine, the State Food and Drug Administration, and the Logistics Support Department of the Central Military Commission and expert members in various related fields22People attended the meeting at the main venue in Beijing, others42Executive members participate in the meeting via remote video.

1,4Month1day, France.OSE ImmunotherapeuticsCompany announces its new anti-cancer vaccineTedopiin non-small cell lung cancerIIIThe clinical trial achieved positive results, and all patients enrolled in the group were treated with immune checkpoint inhibitors (PD-1) resistance or failure, second-line or third-line useTedopivaccine, the one-year overall survival rate reached46%, higher than the pre-specified25%and accept.TedopiThe median overall survival of patients with advanced non-small cell lung cancer treated (OS) reach17.3months, with controlled security.

2,4Month2Researchers at the University of Pittsburgh in the United States have developed a novel method to deliver drugs using a microneedle array to improve drug efficacy. This array is composed400It consists of tiny needles that deliver the spike protein fragments to the skin to produce the strongest immune response. The patch is used like a band-aid, and then a patch needle made entirely of sugar and protein fragments dissolves into the skin, causing the body's immune response.

3,4Month10Day, Henry, USA·Jackson Military Medical Development Foundation and Walter·Researchers from the U.S. Military HIV Research Project Group at the Reed Army Research Institute26Name in acute human immunodeficiency (HIV) patients who started antiretroviral therapy during viral infection were injectedAd26--containing chimerismHIV-1The results show that the vaccine is safe and induces a strong immune response.HIVThe vaccine is safe and effective.

4、4Month12On the same day, the State Food and Drug Administration approved the joint declaration of the Wuhan Institute of Biological Products of the National Pharmaceutical Group and the Wuhan Institute of Viruses of the Chinese Academy of Sciences.-Novel inactivated coronavirus vaccine (Verocells) to conduct phase I clinical trials.

5、4Month14The Ministry of Science and Technology and the Ministry of Finance approved the construction of a national human disease animal model resource bank.